Katarina SjÃ¶green Gleisner

List of Publications by Year
in descending order

39 papers	1,373 citations	331670 21 h-index	330143 37 g-index
39 all docs	39 docs citations	39 times ranked	955 citing authors

#	Article	IF	Citations
1	The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1976-1988.	6.4	179
2	EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2456-2474.	6.4	124
3	Evaluation of quantitative⁹⁰Y SPECT based on experimental phantom studies. Physics in Medicine and Biology, 2008, 53, 5689-5703.	3.0	120
4	Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force. EJNMMI Physics, 2017, 4, 27.	2.7	71
5	EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1778-1809.	6.4	70
6	Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey. EJNMMI Physics, 2017, 4, 28.	2.7	65
7	Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy. EJNMMI Physics, 2018, 5, 12.	2.7	60
8	The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1783-1786.	6.4	48
9	Evaluation of quantitative planar⁹⁰Y bremsstrahlung whole-body imaging. Physics in Medicine and Biology, 2009, 54, 5873-5883.	3.0	45
10	Uncertainty propagation for SPECT/CT-based renal dosimetry in¹⁷⁷Lu peptide receptor radionuclide therapy. Physics in Medicine and Biology, 2015, 60, 8329-8346.	3.0	45
11	Bone Marrow Absorbed Doses and Correlations with Hematologic Response During ¹⁷⁷Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases. Journal of Nuclear Medicine, 2019, 60, 1406-1413.	5.0	41
12	High-Dose Iodine-131-Metaiodobenzylguanidine with Haploidentical Stem Cell Transplantation and Posttransplant Immunotherapy in Children with Relapsed/Refractory Neuroblastoma. Biology of Blood and Marrow Transplantation, 2009, 15, 1077-1085.	2.0	39
13	From fixed activities to personalized treatments in radionuclide therapy: lost in translation?. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 152-154.	6.4	34
14	A multicentre and multi-national evaluation of the accuracy of quantitative Lu-177 SPECT/CT imaging performed within the MRTDosimetry project. EJNMMI Physics, 2021, 8, 55.	2.7	34
15	Pharmacokinetic digital phantoms for accuracy assessment of image-based dosimetry in¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy. Physics in Medicine and Biology, 2015, 60, 6131-6149.	3.0	32
16	Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with¹⁷⁷Lu-DOTATATE. Journal of Nuclear Medicine, 2022, 63, 399-405.	5.0	30
17	Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3830-3840.	6.4	30
18	Consequences of inadvertent radioiodine treatment of Gravesâ€™ disease and thyroid cancer in undiagnosed pregnancy. Can we rely on routine pregnancy testing?. Acta OncolÃ³gica, 2008, 47, 145-149.	1.8	28

#	Article	IF	Citations
19	Long-Term Retention of ¹⁷⁷Lu/^{177m}Lu-DOTATATE in Patients Investigated by Î³-Spectrometry and Î³-Camera Imaging. Journal of Nuclear Medicine, 2015, 56, 976-984.	5.0	27
20	SPECT image segmentation for estimation of tumour volume and activity concentration in 177Lu-DOTATATE radionuclide therapy. EJNMMI Research, 2017, 7, 18.	2.5	26
21	Personalized Dosimetry for Radionuclide Therapy Using Molecular Imaging Tools. Biomedicines, 2016, 4, 25.	3.2	22
22	3-D Image-Based Dosimetry in Radionuclide Therapy. IEEE Transactions on Radiation and Plasma Medical Sciences, 2018, 2, 527-540.	3.7	21
23	On the biologically effective dose (BED)â€"using convolution for calculating the effects of repair: II. Numerical considerations. Physics in Medicine and Biology, 2013, 58, 1529-1548.	3.0	20
24	Hybrid Imaging for Patient-Specific Dosimetry in Radionuclide Therapy. Diagnostics, 2015, 5, 296-317.	2.6	19
25	Wholeâ€remnant and maximumâ€voxel SPECT/CT dosimetry in ¹³¹Iâ€NaI treatments of differentiated thyroid cancer. Medical Physics, 2016, 43, 5279-5287.	3.0	19
26	On the biologically effective dose (BED)â€"using convolution for calculating the effects of repair: I. Analytical considerations. Physics in Medicine and Biology, 2013, 58, 1507-1527.	3.0	18
27	A method for tumor dosimetry based on hybrid planarâ€SPECT/CT images and semiautomatic segmentation. Medical Physics, 2018, 45, 5004-5018.	3.0	16
28	Dosimetric results in treatments of neuroblastoma and neuroendocrine tumors with ¹³¹Iâ€metaiodobenzylguanidine with implications for the activity to administer. Medical Physics, 2015, 42, 3969-3978.	3.0	15
29	Dynamic99mTc-MAG3 renography: images for quality control obtained by combining pharmacokinetic modelling, an anthropomorphic computer phantom and Monte Carlo simulated scintillation camera imaging. Physics in Medicine and Biology, 2013, 58, 3145-3161.	3.0	14
30	Patient-Specific Whole-Body Attenuation Correction Maps from a CT System for Conjugate-View-Based Activity Quantification: Method Development and Evaluation. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 652-664.	1.0	11
31	Biologically effective dose in fractionated molecular radiotherapyâ€"application to treatment of neuroblastoma with131I-mIBG. Physics in Medicine and Biology, 2016, 61, 2532-2551.	3.0	9
32	Comparison of Empiric Versus Dosimetry-Guided Radioiodine Therapy: The Devil Is in the Details. Journal of Nuclear Medicine, 2017, 58, 862-862.	5.0	8
33	Analysis of activity uptake, effective half-life and time-integrated activity for low- and high-risk papillary thyroid cancer patients treated with 1.11â€¯GBq and 3.7â€¯GBq of 131I-NaI respectively. Physica Medica, 2019, 65, 143-149.	0.7	8
34	Parametric Images of Antibody Pharmacokinetics Based on Serial Quantitative Whole-Body Imaging and Blood Sampling. Journal of Nuclear Medicine, 2007, 48, 1369-1378.	5.0	7
35	Development and Evaluation of a Pharmacokinetic Model for Prediction of Radioimmunotherapy Based on Pretherapy Data. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 111-122.	1.0	7
36	Characterisation of a hand-held CZT-based gamma camera for 177Lu imaging. EJNMMI Physics, 2020, 7, 46.	2.7	7

#	Article	IF	Citations
37	Re: Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2019, 30, 2047-2048.	0.5	3
38	Monte Carlo modelling of a compact CZT-based gamma camera with application to 177Lu imaging. EJNMMI Physics, 2022, 9, 35.	2.7	1
39	Radionuclide Metabolic Therapy. , 2013, , .		0